middle.news
Why Immuron’s Latest Trial Missed the Mark but Keeps Eyes on FDA
9:19am on Wednesday 10th of December, 2025 AEDT
•
Biotechnology
Read Story
Why Immuron’s Latest Trial Missed the Mark but Keeps Eyes on FDA
9:19am on Wednesday 10th of December, 2025 AEDT
Key Points
Uniformed Services University trial of third-party IMM-124E failed primary endpoint
Trial product differed in dosing and administration from Immuron’s Travelan
Immuron to propose three-times-daily Travelan dosing at FDA End-of-Phase 2 meeting
Ongoing collaborations with military research institutes on vaccines for Campylobacter, Shigella, and E. coli
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immuron (ASX:IMC)
OPEN ARTICLE